Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies.
Our TransCon technologies can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. In addition to our clinical pipeline in endocrinology rare diseases, we have multiple preclinical programs in oncology, our second therapeutic area.
In endocrinology, our clinical pipeline includes TransCon hGH, for which we have completed the phase 3 heiGHt Trial evaluating once-weekly TransCon hGH compared to a daily growth hormone in children with pediatric growth hormone deficiency (GHD). In March 2019, top-line data were reported for this trial, which met its primary endpoint. We are also developing two additional endocrinology rare disease product candidates, TransCon PTH and TransCon CNP.
In oncology, we have multiple preclinical programs underway including: TransCon Toll-like Receptor 7/8 (TLR7/8) Agonist, TransCon IL-2 β/γ and TransCon Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI).
In addition to our internal programs, we have collaborations focused on developing products in large markets that are of strategic importance. These collaborations are with Sanofi in the field of diabetes and Roche Genentech in the field of ophthalmology.
Additionally, we and an investor syndicate formed VISEN Pharmaceuticals (known as Visen), a company established to develop and commercialize our endocrinology rare disease therapies in Greater China. In connection with its formation, we granted Visen exclusive rights to develop and commercialize certain product candidates based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH and TransCon CNP, in Greater China.
Ascendis Pharma is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (short from “transient conjugation”) to create best-in-class products to address unmet patient needs.